[Edaily Reporter Kwon Oh-seok] #Aptabio announced on the 16th that it has received approval from the U.S. Food and Drug Administration (FDA) to lift the clinical hold and resume Phase 1 clinical trials for "ABF-101," an oral treatment for age-related macular degeneration. Following receipt of this official notice, the company plans to resume the previously suspended clinical trials and drug administration.
Disclosure Plus
Aptabio Lifts Hold on Phase 1 Clinical Trial for 'ABF-101'
Kwon Oh Seok
2026-06-16 11:57:54
Economy
Corporation
IT·Science
Economy
Memory Chips Gain the Upper Hand Thanks to AI… 'First Ever' Reversal in Non-Memory Chip Sales
Forecasts indicate that memory semiconductor sales will surpass non-memory sales for the first time in history this year. While the competition in artificial intelligence (AI) has traditionally focuse…
Corporation
A Ramen Company Has Opened a 'Studio'… K-Food: Content as the Decisive Battleground
Nongshim has “SHIN,” and SamyangFoods has “PEPPO.” Domestic instant noodle companies are going beyond simply creating their own characters and building fictional universes—they are now even establishi…
IT·Science
Two-Way Race Over ‘Proprietary Security AI’… SKT vs. Naver Cloud
(AI-generated image)
Consortia led by SKTelecom(017670)and Naver (NAVER(035420)) Cloud have submitted bids for the government’s “Development of AI Foundation Models Specialized in Cybersecurity” p…
